Lund, Sweden, 2014-08-07 08:45 CEST (GLOBE NEWSWIRE) --
Market penetration for the product cardioREPO (EXINI heart) exceeds expectations. FUJIFILM RI Pharma Co. Ltd carries the exclusive rights to the Japanese version of EXINI’s heart product and has over the first months installed 100 units of the software system cardioREPO in clinics throughout Japan.
The recent introduction onto the Japanese market has been successful both in terms of pace and numbers. The widespread installations are expected to accelerate both clinical use and evaluation processes, resulting in forthcoming medical publications on improvement of quality and productivity for Myocardial Perfusion Scintigraphy.
“Our University Group has, together with a large number of hospitals in Japan, worked closely together with the teams of EXINI and FUJIFILM RI Pharma to develop a user friendly yet extremely advanced software. We will now proceed to evaluate the software from both a technical and a clinical standpoint and subsequently share our findings with the medical community“, comments Dr. Kenichi Nakajima, Kanazawa University
"The rate of installations is impressive and surpasses the launch of our first product, BONENAVI (EXINI boneBSI). It is exciting having FUJIFILM RI Pharma as a strong partner as they play a significant role on the Japanese market, facilitating two products from our software portfolio to be installed in close to all existing nuclear medicine clinics throughout Japan”, comments Magnus Aurell, CEO EXINI Diagnostics AB
About cardioREPO (EXINI heart)
cardioREPO is an advanced customization of the diagnostic software system EXINI heart, providing clinics and specialists with thoroughly specialized information pivotal to managing patients suffering from suspected or known ischemic heart conditions e.g. heart attacks or Angina.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
